Understanding Checkpoint Inhibitors in Oncology

Checkpoint inhibitors target immune checkpoints, allowing the immune system to attack cancer cells that evade detection. These inhibitors, such as CTLA4 and PD1, aim to enhance the immune response against cancer. The adaptation of cancer cells to over-express these proteins can hinder the immune system's recognition of cancer as a threat. By suppressing these checkpoints, checkpoint inhibitors help unleash the immune system against cancer, albeit with the potential for adverse effects on normal cells.